AstraZeneca PLC (AZN) Income Statement
AZN 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsAZN revenue and net income
Where AZN's revenue goes
2025Each bar shows an amount and its share of revenue. AZN kept 17.5% of revenue as net income.
AZN profit margins
AZN growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | +8.6% | +9.8% | +17.2% | +9.0% |
| Gross profit | +9.7% | +14.6% | +17.7% | +9.1% |
| Operating income | +37.4% | +54.1% | +21.6% | +12.8% |
| Net income | +45.8% | +46.1% | +26.3% | +13.8% |
| EPS (diluted) | +59.9% | +25.3% | +25.9% | +7.8% |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
AZN quarterly EPS vs estimates
AstraZeneca beat the analyst EPS estimate in 7 of the last 8 quarters. Next report: October 30, 2026 (estimate $2.16).
AZN income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $58.74B | $54.07B | $45.81B | $44.35B | $37.42B | $26.62B | $24.38B | $22.09B | $22.46B | $23.00B |
| Cost of revenue | $10.63B | $10.21B | $8.27B | $12.39B | $12.44B | $5.30B | $4.92B | $4.94B | $4.32B | $4.13B |
| Gross profit | $48.11B | $43.87B | $37.54B | $31.96B | $24.98B | $21.32B | $19.46B | $17.15B | $18.15B | $18.88B |
| Research & development | $14.23B | $13.58B | $10.94B | $9.76B | $9.74B | $5.99B | $6.06B | $5.93B | $5.76B | $5.89B |
| Sales, general & admin | $20.51B | $20.22B | $18.22B | $17.98B | $15.14B | $11.90B | $11.98B | $10.98B | $10.23B | $9.41B |
| Total operating expenses | $34.36B | $33.86B | $29.35B | $28.20B | $23.92B | $16.16B | $16.54B | $13.77B | $14.47B | $13.97B |
| Operating income | $13.74B | $10.00B | $8.19B | $3.76B | $1.06B | $5.16B | $2.92B | $3.39B | $3.68B | $4.90B |
| Interest income | $360.0M | $345.0M | $301.0M | $81.0M | $43.0M | — | — | — | — | — |
| Interest expense | $1.69B | $1.68B | $1.59B | $1.33B | $1.28B | $1.27B | $1.40B | $1.37B | $1.36B | $1.37B |
| Income before taxes | $12.40B | $8.69B | $6.90B | $2.50B | −$265.0M | $3.92B | $1.55B | $1.99B | $2.23B | $3.55B |
| Income taxes | $2.17B | $1.65B | $938.0M | −$792.0M | −$380.0M | $772.0M | $321.0M | −$57.0M | −$641.0M | $146.0M |
| Net income | $10.26B | $7.04B | $5.96B | $3.29B | $112.0M | $3.20B | $1.33B | $2.15B | $3.00B | $3.50B |
| EBITDA | $19.83B | $15.44B | $13.42B | $9.09B | $5.11B | $8.08B | $6.71B | $7.11B | $6.62B | $7.28B |
| EPS (diluted) | $6.57 | $4.11 | $3.64 | $3.34 | $2.65 | $2.08 | $1.56 | $1.79 | $2.15 | $2.17 |
| Gross margin | 81.9% | 81.1% | 82.0% | 72.1% | 66.8% | 80.1% | 79.8% | 77.7% | 80.8% | 82.1% |
| Operating margin | 23.4% | 18.5% | 17.9% | 8.5% | 2.8% | 19.4% | 12.0% | 15.3% | 16.4% | 21.3% |
| Net margin | 17.5% | 13.0% | 13.0% | 7.4% | 0.3% | 12.0% | 5.5% | 9.8% | 13.4% | 15.2% |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $15.38B | $15.29B | $15.50B | $15.19B | $14.46B | $13.59B | $14.89B | $13.56B | $12.94B | $12.68B | $12.02B | $11.49B |
| Cost of revenue | $2.52B | $2.68B | $3.12B | $2.80B | $2.47B | $2.24B | $2.73B | $3.08B | $2.18B | $2.22B | $2.31B | $2.10B |
| Gross profit | $12.86B | $12.61B | $12.38B | $12.39B | $11.98B | $11.35B | $12.17B | $10.48B | $10.76B | $10.46B | $9.72B | $9.40B |
| Research & development | $4.05B | $3.49B | $3.86B | $3.66B | $3.55B | $3.16B | $4.68B | $3.12B | $3.01B | $2.78B | $3.07B | $2.58B |
| Sales, general & admin | $5.80B | $4.92B | $5.64B | $5.23B | $5.01B | $4.63B | $5.55B | $5.29B | $5.06B | $4.63B | $5.52B | $4.93B |
| Total operating expenses | $9.70B | $8.36B | $9.41B | $8.81B | $8.48B | $7.67B | $10.13B | $8.38B | $8.01B | $7.35B | $8.48B | $7.44B |
| Operating income | $3.16B | $4.25B | $2.98B | $3.58B | $3.51B | $3.67B | $2.04B | $2.11B | $2.75B | $3.12B | $1.23B | $1.95B |
| Interest income | $80.0M | $73.0M | $135.0M | $85.0M | $68.0M | $84.0M | $64.0M | $183.0M | — | — | — | — |
| Interest expense | $435.0M | $393.0M | $472.0M | $434.0M | $439.0M | $349.0M | $429.0M | $457.0M | $443.0M | $413.0M | $445.0M | $392.0M |
| Income before taxes | $2.80B | $3.91B | $2.63B | $3.24B | $3.13B | $3.40B | $1.67B | $1.83B | $2.40B | $2.80B | $897.0M | $1.65B |
| Income taxes | $291.0M | $833.0M | $300.0M | $709.0M | $679.0M | $481.0M | $166.0M | $395.0M | $469.0M | $620.0M | −$62.0M | $274.0M |
| Net income | $2.51B | $3.08B | $2.33B | $2.53B | $2.45B | $2.92B | $1.50B | $1.43B | $1.93B | $2.18B | $960.0M | $1.37B |
| EBITDA | $5.16B | $5.67B | $4.63B | $5.23B | $4.96B | $5.04B | $2.81B | $4.10B | $4.12B | $4.47B | $2.67B | $3.33B |
| EPS (diluted) | $2.63 | $1.29 | — | $1.19 | $0.79 | $1.25 | $1.05 | $1.04 | $0.99 | $1.03 | $0.73 | $0.87 |
| Gross margin | 83.6% | 82.5% | 79.9% | 81.6% | 82.9% | 83.5% | 81.7% | 77.3% | 83.1% | 82.5% | 80.8% | 81.8% |
| Operating margin | 20.6% | 27.8% | 19.2% | 23.6% | 24.3% | 27.0% | 13.7% | 15.5% | 21.2% | 24.6% | 10.3% | 17.0% |
| Net margin | 16.3% | 20.1% | 15.0% | 16.7% | 16.9% | 21.5% | 10.1% | 10.5% | 14.9% | 17.2% | 8.0% | 12.0% |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in AZN's financial statements (latest annual report filed February 24, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
AZN financial results
In fiscal year 2025 (ended December 31, 2025), AstraZeneca reported revenue of $58.7 billion, up 8.6% from the year before. It had net income of $10.3 billion (up 45.8%), a net profit margin of 17.5%. Diluted earnings per share came to $6.57. Over five years revenue grew at an average rate of 17.2% a year.
See the AZN stock overview for the latest quote and news, or the AZN chart for price history and technical indicators.
AZN income statement FAQ
What is AstraZeneca's annual revenue?
AstraZeneca reported total revenue of $58.7 billion for fiscal year 2025, which ended on December 31, 2025. That was up 8.6% from $54.1 billion the previous year.
Is AstraZeneca profitable?
Yes. AstraZeneca reported net income of $10.3 billion in fiscal 2025, a net profit margin of 17.5%; its operating margin was 23.4%.
What is AstraZeneca's gross margin?
AstraZeneca's gross margin was 81.9% in fiscal 2025: for every $100 of revenue, AstraZeneca kept $82 after the direct cost of its products and services.
How much does AstraZeneca spend on research and development?
AstraZeneca spent $14.2 billion on research and development in fiscal 2025, 24.2% of revenue.
How fast is AstraZeneca growing?
Revenue grew 17.2% a year on average over the last five fiscal years, from $26.6 billion to $58.7 billion.
What are AstraZeneca's earnings per share?
AstraZeneca earned $6.57 per diluted share in fiscal 2025, compared with $4.11 a year earlier.
When will AstraZeneca report its next earnings?
AstraZeneca is expected to report results for the quarter ending September 30, 2026 on October 30, 2026 before the market opens.
When does AstraZeneca's fiscal year end?
AstraZeneca's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on February 24, 2026.